Early cancer detection increases survival.
Detecting cancer at the earliest stages can increase a patient’s chance of survival and improve his or her quality of life. Oncoscope has developed an optical biopsy device that helps physicians accurately and instantly identify dysplastic or pre–cancerous tissue for biopsy.
This proven technology will allow physicians to more accurately diagnose a patient’s condition, thereby reducing false negatives and unnecessary surveillance. Such an optical approach can achieve the promise of early detection.
Guided biopsy is the next frontier of
Biopsies are often taken randomly from target tissue, a process associated with many unnecessary biopsies, high costs, and inaccurate diagnoses. Guided biopsies can detect cancers in the earliest phases objectively, non–invasively, and in real–time, potentially leading to fewer biopsy samples while improving diagnostic accuracy and lowering healthcare costs.
Oncoscope delivers guided biopsy.
Oncoscope has created an innovative optical screening platform that uses scattered light to identify cells with enlarged nuclei — the primary early marker for cancer. This optical guide to biopsy system has been shown to increase the effectiveness of physical biopsies used to detect esophageal cancer, the deadliest and fastest-growing cancer today.
With the support of some of the world’s leading gastroenterologists, Oncoscope demonstrated impressive performance for its optical guide to biopsy device in multi–center clinical trials across the United States. In a recent clinical study, Oncoscope’s system accurately detected pre–cancerous tissue in the esophagus 97% of the time.
While esophageal cancer is the primary focus for Oncoscope’s breakthrough technology, this platform has the potential to guide biopsies in the colon, cervix, stomach, lung, bladder, and oral cavity — epithelial tissues where 85% of all cancers begin.